Article révisé par les pairs
Titre:
  • The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.
Auteur:Awada, Ahmad; Cardoso, Fatima; Fontaine, C.; Dirix, Luc Y; De Greve, Jacques; Sotiriou, Christos; Steinseifer, Jutta; Wouters, Carine; Tanaka, Chiaki; Zoellner, Ulrike; Tang, Pui; Piccart-Gebhart, Martine
Informations sur la publication:European journal of cancer, 44, 1, page (84-91)
Statut de publication:Publié, 2008-01
Sujet CREF:Sciences bio-médicales et agricoles
Mots-clés:Breast cancer
Everolimus
Letrozole
mTOR
Pharmacokinetics
Phase I
RAD001
MeSH keywords:Administration, Oral
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols -- adverse effects
Antineoplastic Combined Chemotherapy Protocols -- pharmacokinetics
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- drug therapy
Cohort Studies
Drug Interactions
Feasibility Studies
Female
Humans
Immunosuppressive Agents -- administration & dosage
Immunosuppressive Agents -- adverse effects
Immunosuppressive Agents -- pharmacokinetics
Male
Middle Aged
Nitriles -- administration & dosage
Nitriles -- adverse effects
Nitriles -- pharmacokinetics
Sirolimus -- administration & dosage
Sirolimus -- adverse effects
Sirolimus -- analogs & derivatives
Sirolimus -- pharmacokinetics
Treatment Outcome
Triazoles -- administration & dosage
Triazoles -- adverse effects
Triazoles -- pharmacokinetics
Note générale:Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langue:Anglais
Identificateurs:urn:issn:0959-8049
info:doi/10.1016/j.ejca.2007.10.003
info:pii/S0959-8049(07)00793-9
info:scp/37149020235
info:pmid/18039566

Documents en relation

DI-fusion